Physician

Aman Opneja, MBBS

According to 2025 Medicare claims, Aman Opneja, MBBS (NPI: 1629419494) practices hematology/oncology in the Raleigh-Cary, NC market, with the plurality of this provider's patient population coming from Wake, NC. This provider's primary affiliated billing organization is DUKE HEALTH INTEGRATED PRACTICE, INC. (NPI: 1205553369; TIN: 862109896) and primary practice location at 27609-7340. Opneja is affiliated with the Duke Connected Care, LLC (ACO ID: A2419), participating under the MSSP model.

Opneja's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 77 traditional Medicare patients, billed 375 HCPCS/CPT codes, and received $32,949 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 445 prescription claims across 70 beneficiaries totaling $217,751 in drug costs, led by Eliquis (Apixaban). DME data shows 30 claims. Open Payments data shows 9 records totaling $10,690. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	64	140	$11,392
2020	84	343	$24,648
2021	98	420	$54,084
2022	100	345	$39,401
2023	67	271	$29,471
2024	77	375	$32,949

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	22	71	$2,531
2016	21	85	$3,132
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	23	82	$113,440
2020	44	300	$490,348
2021	52	294	$488,205
2022	49	231	$255,168
2023	59	333	$184,675
2024	70	445	$217,751

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	80	$5,784
2021	N/R	106	$6,227
2022	N/R	N/R	N/R
2023	N/R	12	$8,160
2024	N/R	30	$836

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	13	13	$131
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	16	16	$127
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	31	197	$104
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	40	70	$65
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	18	40	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Eliquis	Apixaban	26	971	$19,481
Dexamethasone	Dexamethasone	35	619	$641
Olanzapine	Olanzapine	31	1,095	$489
Ondansetron Hcl	Ondansetron Hcl	38	1,010	$472
Prochlorperazine Maleate	Prochlorperazine Maleate	24	370	$430

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	19	$629
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	11	$207

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	9	$10,690	ARRAY BIOPHARMA INC
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Aman Opneja, MBBS?

Tedicare shows public-source Medicare data for Aman Opneja, MBBS (NPI 1629419494), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Aman Opneja, MBBS have ACO affiliation data?

Aman Opneja, MBBS is shown with ACO affiliation data for Duke Connected Care, LLC (MSSP, ACO ID A2419).

What billing organization is linked to Aman Opneja, MBBS?

Aman Opneja, MBBS is linked to DUKE HEALTH INTEGRATED PRACTICE, INC. (billing NPI 1205553369) in the available physician profile data.

Does Aman Opneja, MBBS have Open Payments data?

Aman Opneja, MBBS has 9 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.